Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received one prior platinum-based chemotherapy received 175 or 210 mg m(−...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Paz-Ares, L, Ross, H, O'Brien, M, Riviere, A, Gatzemeier, U, Von Pawel, J, Kaukel, E, Freitag, L, Digel, W, Bischoff, H, García-Campelo, R, Iannotti, N, Reiterer, P, Bover, I, Prendiville, J, Eisenfeld, A J, Oldham, F B, Bandstra, B, Singer, J W, Bonomi, P
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2008
Schlagworte:
Clinical Study
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2391114/
https://ncbi.nlm.nih.gov/pubmed/18475293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604372
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge